← All stories
Markets
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company’s Phase 1b trial of PMN310 in patients with early Alzheimer’s disease (AD), including zero cases of amyloid-related imaging abnormalities…
Covered by 1 outlet
All coverage · 1 article